{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated|Treatment of multiple myeloma" in comments (approximate match)
Status:
Investigational
Source:
NCT00435916: Phase 2 Interventional Completed Lymphoma, Large B-Cell, Diffuse
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00989586: Phase 1/Phase 2 Interventional Completed Lymphoma
(2009)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
EU-Orphan Drug:EU/3/14/1423
Source URL:
Class:
PROTEIN
ImMucin is a 21-mer long peptide therapeutic vaccine encoding the entire signal peptide (SP) domain of the MUC1 tumor-associated antigen, which is over expressed by most hematological tumors including multiple myeloma (MM). Preclinical studies of ImMucin and its internal epitopes in multiple myeloma suggested superior immunological and anti-tumor properties compared to other MUC1 TRA‐derived epitopes. ImMucin demonstrated encouraging short and long-term safety profile. Vaccination induced a remarkable anti-MM immune response. However, immunity was transient suggesting a need for boosting. Interestingly, durable disease stabilization was achieved in the third of the patients, continuing despite the loss of immune response in peripheral blood. Moreover, the encouraging responses to subsequent therapies employed at clinical progression, suggest this novel approach to be potentially valuable in the setting of maintenance and/or early biochemical progression.
Status:
First approved in 1955
Class:
PROTEIN
Status:
US Previously Marketed
First marketed in 1921
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT03309111: Phase 1 Interventional Completed Relapsed/Refractory Multiple Myeloma
(2017)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT03582033: Phase 1 Interventional Terminated Multiple Myeloma
(2018)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT03136653: Phase 1/Phase 2 Interventional Completed Multiple Myeloma in Relapse
(2017)
Source URL:
Class:
CONCEPT
Status:
US Approved Rx
(1985)
Source:
NDA020145
(1985)
Source URL:
First marketed in 1921
Source:
Spirit of Glyceryl Trinitrate U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Pentaerythritol tetranitrate is an organic nitrate that has been used for the treatment of angina pectoris. Upon administration, the drug undergoes exstensive metabolism to NO which causes vasodilation and the relaxation of smooth muscle cells. The compound belongs to a familiy of explosive substances and may be used accordingly.